316 related articles for article (PubMed ID: 36713415)
1. Current experimental methods to investigate the impact of specialized pro-resolving lipid mediators on Sjögren's syndrome.
Dos Santos HT; Nam K; Gil D; Yellepeddi V; Baker OJ
Front Immunol; 2022; 13():1094278. PubMed ID: 36713415
[TBL] [Abstract][Full Text] [Related]
2. Aspirin Triggered Resolvin D1 reduces inflammation and restores saliva secretion in a Sjögren's syndrome mouse model.
Dean S; Wang CS; Nam K; Maruyama CL; Trump BG; Baker OJ
Rheumatology (Oxford); 2019 Jul; 58(7):1285-1292. PubMed ID: 30877775
[TBL] [Abstract][Full Text] [Related]
3. Specialized pro-resolving receptors are expressed in salivary glands with Sjögren's syndrome.
Dos Santos HT; Nam K; Maslow F; Trump B; Baker OJ
Ann Diagn Pathol; 2022 Feb; 56():151865. PubMed ID: 34847389
[TBL] [Abstract][Full Text] [Related]
4. Predictive modeling of aspirin-triggered resolvin D1 pharmacokinetics for the study of Sjögren's syndrome.
Yellepeddi VK; Baker OJ
Clin Exp Dent Res; 2020 Apr; 6(2):225-235. PubMed ID: 32250566
[TBL] [Abstract][Full Text] [Related]
5. Sex-mediated elevation of the specialized pro-resolving lipid mediator levels in a Sjögren's syndrome mouse model.
Parashar K; Schulte F; Hardt M; Baker OJ
FASEB J; 2020 Jun; 34(6):7733-7744. PubMed ID: 32277856
[TBL] [Abstract][Full Text] [Related]
6. AT-RvD1 combined with DEX is highly effective in treating TNF-α-mediated disruption of the salivary gland epithelium.
Easley JT; Maruyama CL; Wang CS; Baker OJ
Physiol Rep; 2016 Oct; 4(19):. PubMed ID: 27694530
[TBL] [Abstract][Full Text] [Related]
7. AT-RvD1 Promotes Resolution of Inflammation in NOD/ShiLtJ mice.
Wang CS; Maruyama CL; Easley JT; Trump BG; Baker OJ
Sci Rep; 2017 Mar; 7():45525. PubMed ID: 28361884
[TBL] [Abstract][Full Text] [Related]
8. ALX/FPR2 receptor for RvD1 is expressed and functional in salivary glands.
Nelson JW; Leigh NJ; Mellas RE; McCall AD; Aguirre A; Baker OJ
Am J Physiol Cell Physiol; 2014 Jan; 306(2):C178-85. PubMed ID: 24259417
[TBL] [Abstract][Full Text] [Related]
9. Expression of resolvin D1 biosynthetic pathways in salivary epithelium.
Leigh NJ; Nelson JW; Mellas RE; Aguirre A; Baker OJ
J Dent Res; 2014 Mar; 93(3):300-5. PubMed ID: 24389810
[TBL] [Abstract][Full Text] [Related]
10. Metabolipidomic profiling reveals an age-related deficiency of skeletal muscle pro-resolving mediators that contributes to maladaptive tissue remodeling.
Markworth JF; Brown LA; Lim E; Castor-Macias JA; Larouche J; Macpherson PCD; Davis C; Aguilar CA; Maddipati KR; Brooks SV
Aging Cell; 2021 Jun; 20(6):e13393. PubMed ID: 34075679
[TBL] [Abstract][Full Text] [Related]
11. Predicting Resolvin D1 Pharmacokinetics in Humans with Physiologically-Based Pharmacokinetic Modeling.
Yellepeddi VK; Parashar K; Dean SM; Watt KM; Constance JE; Baker OJ
Clin Transl Sci; 2021 Mar; 14(2):683-691. PubMed ID: 33202089
[TBL] [Abstract][Full Text] [Related]
12. Aspirin-Triggered Resolvin D1 Versus Dexamethasone in the Treatment of Sjögren's Syndrome-Like NOD/ShiLtJ Mice - A Pilot Study.
Easley JT; Nelson JW; Mellas RE; Sommakia S; Wu C; Trump B; Baker OJ
J Rheum Dis Treat; 2015; 1(4):. PubMed ID: 27110599
[TBL] [Abstract][Full Text] [Related]
13. Resolvin D1 prevents TNF-α-mediated disruption of salivary epithelial formation.
Odusanwo O; Chinthamani S; McCall A; Duffey ME; Baker OJ
Am J Physiol Cell Physiol; 2012 May; 302(9):C1331-45. PubMed ID: 22237406
[TBL] [Abstract][Full Text] [Related]
14. Cytokine concentrations in stimulated whole saliva among patients with primary Sjögren's syndrome, secondary Sjögren's syndrome, and patients with primary Sjögren's syndrome receiving varying doses of interferon for symptomatic treatment of the condition: a preliminary study.
Streckfus C; Bigler L; Navazesh M; Al-Hashimi I
Clin Oral Investig; 2001 Jun; 5(2):133-5. PubMed ID: 11480812
[TBL] [Abstract][Full Text] [Related]
15. The influence of sex steroids on Sjögren's syndrome.
Porola P; Laine M; Virkki L; Poduval P; Konttinen YT
Ann N Y Acad Sci; 2007 Jun; 1108():426-32. PubMed ID: 17894007
[TBL] [Abstract][Full Text] [Related]
16. A novel anti-inflammatory and pro-resolving role for resolvin D1 in acute cigarette smoke-induced lung inflammation.
Hsiao HM; Sapinoro RE; Thatcher TH; Croasdell A; Levy EP; Fulton RA; Olsen KC; Pollock SJ; Serhan CN; Phipps RP; Sime PJ
PLoS One; 2013; 8(3):e58258. PubMed ID: 23484005
[TBL] [Abstract][Full Text] [Related]
17. Low-dose interleukin-2 can improve salivary secretion but not lymphocyte infiltration of salivary glands in a murine model of Sjögren's syndrome.
Wen J; Zhu F; Yu X; Xie H; Li C
BMC Immunol; 2022 Oct; 23(1):49. PubMed ID: 36244973
[TBL] [Abstract][Full Text] [Related]
18. Quantitative Assessment of Salivary Gland Parenchymal Vascularization Using Power Doppler Ultrasound and Superb Microvascular Imaging: A Potential Tool in the Diagnosis of Sjögren’s Syndrome.
Ustabaşıoğlu FE; Korkmaz S; İlgen U; Solak S; Kula O; Turan S; Emmüngil H
Balkan Med J; 2020 Jun; 37(4):203-207. PubMed ID: 32270946
[TBL] [Abstract][Full Text] [Related]
19. Autoimmune hemolytic anemia in an elderly patient with primary Sjögren's syndrome.
Kikawada M; Watanabe D; Kimura A; Hanyu H; Serizawa H; Iwamoto T
Intern Med; 2005 Dec; 44(12):1312-5. PubMed ID: 16415556
[TBL] [Abstract][Full Text] [Related]
20. The complexity of Sjögren's syndrome: novel aspects on pathogenesis.
Jonsson R; Vogelsang P; Volchenkov R; Espinosa A; Wahren-Herlenius M; Appel S
Immunol Lett; 2011 Dec; 141(1):1-9. PubMed ID: 21777618
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
